Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379(9817):738–47.
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 Vaccination in a large Health Care Organization. N Engl J Med. 2021;385(23):2132–9.
Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. 2021;6(10):1202–6.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
Mei R, Raschi E, Forcesi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. Int J Cardiol. 2018;273:183–6.
Navar AM, McNally E, Yancy CW, O’Gara PT, Bonow RO. Temporal associations between immunization with the COVID-19 mRNA vaccines and myocarditis: The Vaccine Safety Surveillance System is working. JAMA Cardiol. 2021;6(10):1117–8.
Swissmedic [Internet]. Bern: Schweizerisches Heilmittelinstitut; c2019 [cited 2022 Jan 13]. Untersuchung von Berichten über Myokarditiden in Zusammenhangmit mRNA Impfstoffen gegen Covid-19. Verfügbar unter:
https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/untersuchung-berichten-ueber-myokarditiden-zusammenhang-mrna-impfstoffe.html
Haaf P, Kuster GM, Mueller C, Berger CT, Monney P, Burger P, et al. The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly. 2021;151:w30087.
Zürich GK, Hg. Information für unter 30-Jährige: Impfung soll möglichst mit Comirnaty© (Pfizer/BioNTech) erfolgen [Internet]. Zürich: GesundheitsdirektionKanton Zürich; 2021 [cited 2021 Nov 30]. Verfügbarunter:
https://www.zh.ch/de/gesundheit/coronavirus/coronavirus-impfung.html#-160365864